935467-22-4Relevant articles and documents
COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS
-
Paragraph 00690, (2017/12/29)
Described herein are methods of treating a metabolic disorder in an individual in need thereof, comprising co-administering to the individual a therapeutically effective amount of an FXR modulator, and at least one second agent that is an CCR2/CCR5 antagonist, ASKl inhibitor, DPP-IV inhibitor, caspase protease inhibitor, SGLT2 inhibitor, acetyl-CoA carboxylase (ACC) inhibitor, diacyl glycerol acyltransferase-1 inhibitor, sodium -bile acid cotransporter-inhibitor, TLR-4 antagonist, PPAR alpha/delta agonist, or GLP-1 agonist, or a combination thereof.
Synthesis of a highly functionalised azepine via a new TBSOTf-mediated cyclisation of a terminal formamide
Heuser, Stefan
, p. 497 - 499 (2007/12/25)
The synthesis of a highly functionalised azepine which can be further derivatised by common chemical transformations is described herein. The present synthesis comprises high-yielding reaction steps and features a new method for the synthesis of azepines via TBSOTf-mediated cyclisation of terminal formamides. Georg Thieme Verlag Stuttgart.